Abeona Treats First Commercial Patient With FDA-Approved ZEVASKYN Gene Therapy for RDEB
Summary: Abeona Therapeutics announced the first commercial administration of ZEVASKYN (prademagene zamikeracel), the first FDA-approved autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The milestone treatment was performed at Lucile Packard Children’s Hospital Stanford under Dr. Joyce Teng. Additional patients are already scheduled for 2026 across Abeona’s growing network of Qualified Treatment Centers (QTCs). ZEVASKYN delivers functional COL7A1 via patient-derived keratinocytes, enabling durable wound closure in a condition historically managed only symptomatically.
Key Highlights:
- First commercial dose given Dec 2025 at Stanford.
- Multiple patients scheduled for early 2026.
- ZEVASKYN: Single topical application post-debridement; restores anchoring fibrils.
- Indication: Adults and children ≥2 years with RDEB junctional wounds (arms, legs, trunk).
- Clinical foundation: Pivotal Phase 3 VIITAL study met primary (≥50% large chronic wound healing) and secondary endpoints.
Keywords: ZEVASKYN, Abeona, RDEB, gene therapy, first commercial, Joyce Teng, Stanford